These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 26659106)

  • 1. Data Integrity-A Study of Current Regulatory Thinking and Action.
    Shafiei N; De Montardy R; Rivera-Martinez E
    PDA J Pharm Sci Technol; 2015; 69(6):762-70. PubMed ID: 26659106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Provable Data Integrity in the Pharmaceutical Industry Based on Version Control Systems and the Blockchain.
    Steinwandter V; Herwig C
    PDA J Pharm Sci Technol; 2019; 73(4):373-390. PubMed ID: 30770485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When government agencies turn to unregulated drug sources: Implications for the drug supply chain and public health are grave.
    Yadav P; Weintraub RL; Stergachis A
    J Am Pharm Assoc (2003); 2018; 58(5):477-480. PubMed ID: 30077566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Data Integrity: History, Issues, and Remediation of Issues.
    Rattan AK
    PDA J Pharm Sci Technol; 2018; 72(2):105-116. PubMed ID: 29158286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UK medicines regulation: responding to current challenges.
    Richards N; Hudson I
    Br J Clin Pharmacol; 2016 Dec; 82(6):1471-1476. PubMed ID: 27580254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulation.
    Pignatti F; Gravanis I; Herold R; Vamvakas S; Jonsson B; Marty M
    Clin Cancer Res; 2011 Aug; 17(16):5220-5. PubMed ID: 21844037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A QRM Discussion of Microbial Contamination of Non-sterile Drug Products, Using FDA and EMA Warning Letters Recorded between 2008 and 2016.
    Santos AMC; Doria MS; Meirinhos-Soares L; Almeida AJ; Menezes JC
    PDA J Pharm Sci Technol; 2018; 72(1):62-72. PubMed ID: 29242394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The regulatory framework for complementary and alternative medicines in Europe].
    Knöss W; Stolte F; Reh K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):771-8. PubMed ID: 18584103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future development of global regulations of Chinese herbal products.
    Fan TP; Deal G; Koo HL; Rees D; Sun H; Chen S; Dou JH; Makarov VG; Pozharitskaya ON; Shikov AN; Kim YS; Huang YT; Chang YS; Jia W; Dias A; Wong VC; Chan K
    J Ethnopharmacol; 2012 Apr; 140(3):568-86. PubMed ID: 22373513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey.
    Oner ZG; Michel SLJ; Polli JE
    Ann N Y Acad Sci; 2017 Nov; 1407(1):26-38. PubMed ID: 29090833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The US Opioid Crisis: Current Federal and State Legal Issues.
    Soelberg CD; Brown RE; Du Vivier D; Meyer JE; Ramachandran BK
    Anesth Analg; 2017 Nov; 125(5):1675-1681. PubMed ID: 29049113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Regulatory Trends in Pharmaceutical Manufacturing and their Impact on the Industry.
    Tabersky D; Woelfle M; Ruess JA; Brem S; Brombacher S
    Chimia (Aarau); 2018 Mar; 72(3):146-150. PubMed ID: 29631666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.
    Vilhelmsson A; Davis C; Mulinari S
    PLoS Med; 2016 Jan; 13(1):e1001945. PubMed ID: 26812151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global Regulatory Landscape.
    Matsuda Y
    AAPS PharmSciTech; 2018 Dec; 20(1):2. PubMed ID: 30560302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Utility of Remote Inspections During the COVID-19 Health Emergency and in the Postpandemic Setting.
    Mofid S; Bolislis WR; Brading C; Hamilton N; Hardit C; Nagaoka M; Parain J; Zanta M; Kühler TC
    Clin Ther; 2021 Dec; 43(12):2046-2063. PubMed ID: 34740466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The patients' and consumers' working party at the European Medicines Agency: a model of interaction between patients, consumers, and medicines regulatory authorities.
    Moulon I; Dedes N
    J Ambul Care Manage; 2010; 33(3):190-7. PubMed ID: 20539145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Regulatory aspects of biosimilars. Myths and facts].
    Schneider CK; Weise M
    Z Rheumatol; 2015 Oct; 74(8):695-700. PubMed ID: 26385104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it possible for FDA regulatory scientists and industry scientists to work together?
    Woosley RL
    Clin Pharmacol Ther; 2012 Mar; 91(3):390-2. PubMed ID: 22343817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.